Non-alcoholic steatohepatitis (NASH) continues to increase in prevalence worldwide and is often
associated with obesity and diabetes. Currently there are no approved therapies for NASH which
has the potential to progress to liver cirrhosis, hepatocellular carcinoma and ultimately end-stage
liver disease. As there is no one animal model which fully mimics the disease in man choosing the
most appropriate with translatability to the clinic can be a challenge. Many of the dietary-induced
NASH models require 24-52 weeks, making therapy assessments time consuming and costly. We
have established a mouse model of NASH with key similarities to man and a swift progression to
steatohepatitis and fibrosis.
For more details or information on how we can support your project please complete the contact form.